Holbrook E K Kohrt
283 works · 18,495 citations · h-index 57
Top works
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
- New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- Systematic review: lamivudine prophylaxis for chemotherapy‐induced reactivation of chronic hepatitis B virus infection
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- Targeting CD137 enhances the efficacy of cetuximab
- Biomarkers associated with checkpoint inhibitors
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.
- Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
- Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors